Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

Publication Type:

Journal Article


Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Volume 26, Issue 11, p.2323-8 (2015)


Biologics Production Core Facility, Research Trials Office Core Facility - Biostatistics Service, Specimen Processing Core Facility


High dose therapy and autologous stem cell transplantation (ASCT) improves outcomes for patients with mantle cell lymphoma (MCL), but relapse ultimately occurs in most patients. Recently presented interim results from a phase III prospective trial suggest maintenance rituximab (MR) after ASCT for MCL improves progression-free survival (PFS). The maturation of these data and any benefit of MR on overall survival (OS) remain to be defined.